Hannah Bower (H Bower)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 11

Top Topics

Rheumatoid Arthritis

Venous Thromboembolism

Community Dwelling

Clinical Practice

Top Venues

Annals of the rheumatic diseases

Scandinavian journal of rheumatology

Rheumatology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Johan Askling
Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis. RMD open 9 (4) (2023)
Viking Huss, Hannah Bower, Karin Hellgren, Thomas Frisell, Johan Askling, null null, null null
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Annals of the rheumatic diseases (2023)
Thomas Frisell, Hannah Bower, Matilda Morin, Eva Baecklund, Daniela Di Giuseppe, Bénédicte Delcoigne, Nils Feltelius, Helena Forsblad-d'Elia, Elisabet Lindqvist, Ulf Lindström, Johan Askling, null null
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Annals of the rheumatic diseases (2023)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Ulf Lindström, Carl Turesson, Katerina Chatzidionysiou, Elisabet Lindqvist, Ann Knight, Helena Forsblad-d'Elia, Johan Askling
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. RMD open 9 (4) (2023)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Ulf Lindström, Carl Turesson, Katerina Chatzidionysiou, Elisabet Lindqvist, Ann Knight, Helena Forsblad-d'Elia, Johan Askling
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. RMD open 9 (4) (2023)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Ulf Lindström, Carl Turesson, Katerina Chatzidionysiou, Elisabet Lindqvist, Ann Knight, Helena Forsblad-d'Elia, Johan Askling
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. RMD open 9 (4) (2023)
Viktor Molander, Hannah Bower, Johan Askling
Validation and characterization of venous thromboembolism diagnoses in the Swedish National Patient Register among patients with rheumatoid arthritis. Scandinavian journal of rheumatology (2022)
Daniela di Giuseppe, Ulf Lindström, Hannah Bower, Bénédicte Delcoigne, Thomas Frisell, Katerina Chatzidionysiou, Christopher Sjöwall, Elisabet Lindqvist, Johan Askling
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Rheumatology (Oxford, England) 61 (9) (2022)
Viktor Molander, Hannah Bower, Thomas Frisell, Bénédicte Delcoigne, Daniela Di Giuseppe, Johan Askling, null null
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Annals of the rheumatic diseases (2022)
Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Johan Askling
Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19? Annals of the rheumatic diseases (2021)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Gerd-Marfie Ahlenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad-d'Elia, Alf Kastbom, Lars Klareskog, Elisabet Lindqvist, Ulf Lindström, Carl Turesson, Christopher Sjöwall, Johan Askling, null null
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD open 7 (3) (2021)